{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 477243444
| IUPAC_name = 6-Amino-2-(fluoromethyl)-3-(2-methylphenyl)quinazolin-4-one
| image = Afloqualone.svg
| width = 200

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|afloqualone}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = Unscheduled <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status = 
| routes_of_administration =  

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 56287-74-2
| ATC_prefix = none
| ATC_suffix =  
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 2105918
| PubChem = 2040
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 1960
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = CO4U2C8ORZ
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01638

<!--Chemical data-->
| C=16 | H=14 | F=1 | N=3 | O=1 
| molecular_weight = 283.3
| smiles = O=C1C2=CC(N)=CC=C2N=C(CF)N1C3=CC=CC=C3C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C16H14FN3O/c1-10-4-2-3-5-14(10)20-15(9-17)19-13-7-6-11(18)8-12(13)16(20)21/h2-8H,9,18H2,1H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = VDOSWXIDETXFET-UHFFFAOYSA-N
}}

'''Afloqualone''' (Arofuto) is a [[quinazolinone]] family [[GABAergic]] [[drug]] and is an analogue of [[methaqualone]] developed in the 1970s by a team at Tanabe Seiyaku.<ref>US Patent 3966731 - 2-Fluoromethyl-3-o-tolyl-6-amino-4(3H)-quinazolinone</ref> It has [[sedative]] and [[muscle relaxant|muscle-relaxant]] effects resulting from its agonist activity at the Î² subtype of the [[GABAA receptor|GABA<sub>a</sub> receptor]] ,<ref>Ochiai T, Ishida R. Pharmacological studies on 6-amino- 2-fluoromethyl- 3-(O-tolyl)- 4(3H)- quinazolinone (afloqualone), a new centrally acting muscle relaxant. (II) Effects on the spinal reflex potential and the rigidity. Japanese Journal of Pharmacology. 1982 Jun;32(3):427-38.</ref> and has had some clinical use, although it causes [[photosensitization]] as a side-effect that can cause skin problems such as [[dermatitis]].<ref>Ishikawa T, Kamide R, Niimura M. Photoleukomelanodermatitis (Kobori) induced by afloqualone. Journal of Dermatology. 1994 Jun;21(6):430-3.</ref>

== See also ==
* [[Methaqualone]]
* [[Diproqualone]]
* [[Etaqualone]]
* [[Methylmethaqualone]]
* [[Mecloqualone]]
* [[Mebroqualone]]
* [[Cloroqualone]]
* [[Nitromethaqualone]]

== References ==
{{reflist}}

{{Sedatives}}
{{GABAAR PAMs}}

[[Category:Sedatives]]
[[Category:Muscle relaxants]]
[[Category:Organofluorides]]
[[Category:Quinazolinones]]
[[Category:GABAA receptor positive allosteric modulators]]


{{musculoskeletal-drug-stub}}
{{sedative-stub}}